In addition, the presence of high microsatellite instability (MSI-high) and mismatch repair can indicate the use of pembrolizumab in uterine cancer, and the presence of programmed cell death protein 1 (PD-1) or a combined positive score can indicate the use of pembrolizumab in cervical cancer [11]. Here, PDCD1 is linked to cervical cancer.